Lisa Walter
Stock Analyst at RBC Capital
(3.39)
# 920
Out of 5,173 analysts
16
Total ratings
50%
Success rate
8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $32 → $35 | $9.23 | +279.20% | 3 | Mar 19, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $140 → $130 | $84.65 | +53.57% | 2 | Mar 17, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $45 → $42 | $27.62 | +52.06% | 3 | Feb 27, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $587 → $643 | $521.22 | +23.36% | 3 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $22 → $21 | $17.57 | +19.52% | 2 | Feb 25, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $7.65 | +109.15% | 1 | Nov 14, 2025 | |
| EYPT EyePoint | Maintains: Outperform | $28 → $39 | $12.83 | +203.98% | 2 | Nov 6, 2025 |
4D Molecular Therapeutics
Mar 19, 2026
Maintains: Outperform
Price Target: $32 → $35
Current: $9.23
Upside: +279.20%
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Outperform
Price Target: $140 → $130
Current: $84.65
Upside: +53.57%
Viridian Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $45 → $42
Current: $27.62
Upside: +52.06%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $587 → $643
Current: $521.22
Upside: +23.36%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $21
Current: $17.57
Upside: +19.52%
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $7.65
Upside: +109.15%
EyePoint
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $12.83
Upside: +203.98%